By: Michelle Flores, PharmD Candidate c/o 2027             Schizophrenia impacts an estimated 24 million individuals globally, with roughly 60% of those affected experiencing negative symptoms. These symptoms, which are a cornerstone of the condition alongside positive symptoms and cognitive impairment, are divided into two categories: experiential and expressive. Experiential symptoms manifest as a lack of…

By Maimuna Maula, PharmD Candidate c/o 2026 On July 23rd, 2025, the FDA approved VOSTALLY (ramipril) Oral Solution by Rosemont Pharmaceuticals Inc. This is an angiotensin converting enzyme (ACE) inhibitor that offers patients a once-daily dosing in an oral liquid form – a viable alternative for individuals who have difficulty swallowing pill formulations.1 Hypertension is…

By: Alba Dona, PharmD Candidate c/o 2027 Over the past few years, technology has transformed almost every aspect of medicine. Tools such as electronic health records, artificial intelligence, e-prescribing, and telehealth platforms have changed the way patients interact with providers and access treatment. Patients can communicate with providers over the phone or by video call,…

By: Amanda Kastel PharmD Candidate c/o 2027  Sleep aid medications are widely used throughout the United States and have long been viewed as a “quick fix” to treat insomnia. In a survey conducted by the American Academy of Sleep Medicine, out of 2,010 adults in the United States, 20% reported using over-the-counter (OTC) medications to…